BridgeMD
New treatment option for Chronic Kidney Diseases
Official title Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
ClinicalTrials.gov ID: NCT03471117
What this study is testing
What is Pioglitazone?
Pioglitazone is an investigational medicine, given as an once-daily, being studied as a potential treatment for chronic kidney diseases.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 35 to 70
You may be able to join if
- CKD patients classified as Stage 3 and 4 of National Kidney Foundation Classification with estimated glomerular filtration rate (GFR) between 15 and...
- Men and women 35 to 70 years of age
You likely can't join if
- Allergy to Glitazones
- Myocardial infarction
- Heart failure
- Angina
- History of kidney stones
- Liver disease (abnormal liver enzymes)
See the full eligibility criteria
- CKD patients classified as Stage 3 and 4 of National Kidney Foundation Classification with estimated glomerular filtration rate (GFR) between 15 and 59 mL/min/1.73 m2 according to the Modification of Diet in Renal...
- Men and women 35 to 70 years of age
- Allergy to Glitazones
- Myocardial infarction
- Heart failure
- Angina
- History of kidney stones
- Liver disease (abnormal liver enzymes)
- Anemia (hemoglobin \<8 g/dl)
- Cancer with current treatment
- Previous organ transplantation
- Immunosuppressant therapy
- Human immunodeficiency virus infection
- Pregnancy or lactating
- Current tobacco use
- Dilantin and oral contraceptive usage due to potential drug interaction with glitazones
- Self-identified history of hypoglycemia
The study team makes the final eligibility decision.
Where it's taking place
- Arlington, Texas, United States
- Dallas, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 35 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Arlington, Texas, United States; Dallas, Texas, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.